Back to Search Start Over

Evaluation of the influenza-like illness case definition and the acute respiratory infection case definition in the diagnosis of influenza and COVID-19 in healthcare personnel.

Authors :
Maltezou HC
Sourri F
Lemonakis N
Karapanou A
Giannouchos TV
Gamaletsou MN
Koukou DM
Souliotis K
Lourida A
Panagopoulos P
Hatzigeorgiou D
Sipsas NV
Source :
Infection, disease & health [Infect Dis Health] 2024 Sep 16. Date of Electronic Publication: 2024 Sep 16.
Publication Year :
2024
Publisher :
Ahead of Print

Abstract

Background: To evaluate the influenza-like illness (ILI) and acute respiratory infection (ARI) case definitions in the diagnosis of COVID-19 and influenza in healthcare personnel (HCP).<br />Methods: We followed a cohort of 5752 HCP from November 2022 to May 2023. Symptomatic HCP were tested for SARS-CoV-2 and influenza by real-time PCR and/or rapid antigen detection test. ILI was defined as the sudden onset of ≥1 systemic symptom and ≥1 respiratory symptom. ARI was defined as the sudden onset of ≥1 respiratory symptom. Patients with respiratory symptoms were grouped either as ILI or as ARI based on the presence of fever, malaise, headache and/or myalgia.<br />Results: Overall, 466 ILI cases and 383 ARI cases occurred. HCP with ILI had an adjusted odds ratio (aOR) of 22.05 [95% confidence interval (CI): 6.23-78.04] to be diagnosed with influenza. HCP with ARI had an aOR of 2.70 (95% CI: 1.88-3.88) to be diagnosed with COVID-19. The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of ILI for influenza were 96.6%, 49.9%, 18.2%, and 99.2%, respectively. The sensitivity, specificity, PPV, and NPV of ARI for COVID-19 were 51.7%, 73.6%, 84.9%, and 34.8%, respectively. ILI and ARI had an overall correct classification rate of 89.6% and 74.1%, respectively.<br />Conclusion: Our findings support the use of both ILI and ARI case definitions in the diagnosis of influenza and COVID-19 in HCP.<br />Competing Interests: Declaration of competing interest Dr Maltezou received an honorarium from Novavax to participate in a symposium. The authors have no conflict of interest to declare.<br /> (Copyright © 2024 Australasian College for Infection Prevention and Control. Published by Elsevier B.V. All rights reserved.)

Details

Language :
English
ISSN :
2468-0869
Database :
MEDLINE
Journal :
Infection, disease & health
Publication Type :
Academic Journal
Accession number :
39289046
Full Text :
https://doi.org/10.1016/j.idh.2024.08.002